Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma

Abstract

Criteria for mGBM may require further refinement and validation. <i>CDKN2A/B</i> deletion, but not <i>TERT</i> mutation or <i>EGFR</i> amplification, may be an independent prognostic biomarker for IDH-wildtype GBM patients.